Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Investing Activities (2016 - 2025)

Cytokinetics (CYTK) has disclosed Cash from Investing Activities for 16 consecutive years, with $680.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities changed N/A to $680.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $90.0 million, a N/A change, with the full-year FY2025 number at $16.7 million, up 103.01% from a year prior.
  • Cash from Investing Activities was $680.6 million for Q4 2025 at Cytokinetics, up from $106.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $680.6 million in Q4 2025 to a low of -$651.5 million in Q2 2024.
  • A 5-year average of -$2.8 million and a median of $29.2 million in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 1118.33% in 2022, then soared 357.47% in 2023.
  • Cytokinetics' Cash from Investing Activities stood at $47.3 million in 2021, then tumbled by 38.21% to $29.2 million in 2022, then plummeted by 378.34% to -$81.4 million in 2023, then soared by 44.66% to -$45.1 million in 2024, then skyrocketed by 1610.72% to $680.6 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Cash from Investing Activities are $680.6 million (Q4 2025), $106.0 million (Q1 2025), and -$45.1 million (Q3 2024).